What it sells
Targeting Cancer with Click Chemistry
Business model breakdown
Buyer: who owns the budget?
Pharma and biotech business-development and oncology R&D teams seeking pre-targeting collaborations (site invites partners to contact bd@shasqi.com).
Trigger: what makes them buy now?
Less than 1% of administered drugs reach the intended location in the body; ADC and radiopharma programs are limited by off-target toxicity and a narrow therapeutic window.
Workflow: what inputs become what output?
Pre-targeting in three steps: infuse a clickable binder that attaches to tumor antigens and clears elsewhere, infuse a clickable inactive payload (radioisotope or cancer drug), then the payload clicks with the binder at the tumor and is activated.
Economics: what it saves and how it charges
UnverifiedPlatform-and-pipeline drug developer: the pipeline page offers collaborations on antigen-targeted CAPAC combinations; revenue would come from partnerships and licensing and from advancing its own therapies (no terms stated).
Distribution: how it reaches customers
Business-development led collaborations: the pipeline page asks interested parties to email bd@shasqi.com.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2015 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.